Seaport Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

  • Employees
  • 58

Employees

  • Stock Symbol
  • SPTX

Stock Symbol

  • Share Price
  • $18.05
  • (As of Friday Closing)

Seaport Therapeutics General Information

Description

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Contact Information

Ownership Status
Publicly Held
Financing Status
Venture Capital-Backed
Corporate Office
  • 101 Seaport Boulevard, Floor 12
  • Seaport Boston
  • Boston, MA 02210
  • United States
+1 (617)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 101 Seaport Boulevard, Floor 12
  • Seaport Boston
  • Boston, MA 02210
  • United States
+1 (617)

Seaport Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Seaport Therapeutics Stock Performance

As of 20-Nov-2026, Seaport Therapeutics’s stock price is $18.05. Its current market cap is $966M with 53.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$18.05 $18.32 $14.85 - $28.38 $966M 53.5M 257K -$4.35

Seaport Therapeutics Financials Summary

As of 30-Sep-2026, Seaport Therapeutics has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024
EV 811,418
Revenue 0 0 0
EBITDA (147,507) (84,106) (52,202)
Net Income (138,537) (74,881) (46,879)
Total Assets 417,624 249,009 315,777
Total Debt 4,686 5,081 5,006
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Seaport Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Seaport Therapeutics‘s full profile, request access.

Request a free trial

Seaport Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Seaport Therapeutics‘s full profile, request access.

Request a free trial

Seaport Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of n
Drug Discovery
Boston, MA
58 As of 2026

Solana Beach, CA
 

Radnor, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Seaport Therapeutics Competitors (3)

One of Seaport Therapeutics’s 3 competitors is Eumentis Therapeutics, a Venture Capital-Backed company based in Solana Beach, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Eumentis Therapeutics Venture Capital-Backed Solana Beach, CA
Marinus Pharmaceuticals Private Equity-Backed Radnor, PA
Arialys Therapeutics Venture Capital-Backed La Jolla, CA
You’re viewing 3 of 3 competitors. Get the full list »

Seaport Therapeutics Patents

Seaport Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026180971-A1 Cbd prodrug formulation and methods of treatment Pending 25-Feb-2025
AU-2024404697-A1 Lipid prodrugs of agomelatine Pending 19-Dec-2023
EP-4827814-A1 Lipid prodrugs of agomelatine Pending 19-Dec-2023
WO-2025137181-A1 Lipid prodrugs of agomelatine Inactive 19-Dec-2023
AU-2024382402-A1 Lipid prodrugs of allopregnanolone and uses thereof Pending 13-Nov-2023 A61P25/24
To view Seaport Therapeutics’s complete patent history, request access »

Seaport Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Seaport Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Seaport Therapeutics‘s full profile, request access.

Request a free trial

Seaport Therapeutics FAQs

  • When was Seaport Therapeutics founded?

    Seaport Therapeutics was founded in 2020.

  • Where is Seaport Therapeutics headquartered?

    Seaport Therapeutics is headquartered in Boston, MA.

  • What is the size of Seaport Therapeutics?

    Seaport Therapeutics has 58 total employees.

  • What industry is Seaport Therapeutics in?

    Seaport Therapeutics’s primary industry is Drug Discovery.

  • Is Seaport Therapeutics a private or public company?

    Seaport Therapeutics is a Public company.

  • What is Seaport Therapeutics’s stock symbol?

    The ticker symbol for Seaport Therapeutics is SPTX.

  • What is the current stock price of Seaport Therapeutics?

    As of 20-Nov-2026 the stock price of Seaport Therapeutics is $18.05.

  • What is the current market cap of Seaport Therapeutics?

    The current market capitalization of Seaport Therapeutics is $966M.

  • Who are Seaport Therapeutics’s competitors?

    Eumentis Therapeutics, Marinus Pharmaceuticals, and Arialys Therapeutics are competitors of Seaport Therapeutics.

  • What is Seaport Therapeutics’s annual earnings per share (EPS)?

    Seaport Therapeutics’s EPS for 12 months was -$4.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process